Alamar Biosciences, Inc. Common Stock (ALMR)vsBoston Scientific Corp (BSX)
ALMR
Alamar Biosciences, Inc. Common Stock
$20.80
+1.41%
HEALTHCARE · Cap: $1.52B
BSX
Boston Scientific Corp
$48.55
-0.55%
HEALTHCARE · Cap: $70.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 23552% more annual revenue ($20.61B vs $87.16M). BSX leads profitability with a 17.3% profit margin vs -49.9%. BSX earns a higher WallStSmart Score of 76/100 (B+).
ALMR
Avoid24
out of 100
Grade: F
BSX
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALMR.
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 98.9% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -33.6% — below average capital efficiency
Negative free cash flow — burning cash
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : ALMR
The strongest argument for ALMR centers on Revenue Growth, Debt/Equity. Revenue growth of 98.9% demonstrates continued momentum.
Bull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : ALMR
The primary concerns for ALMR are EPS Growth, Market Cap, Return on Equity.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Key Dynamics to Monitor
ALMR profiles as a hypergrowth stock while BSX is a mature play — different risk/reward profiles.
ALMR is growing revenue faster at 98.9% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BSX scores higher overall (76/100 vs 24/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alamar Biosciences, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases, leveraging its proprietary technologies to enhance patient care and treatment outcomes. The company's advanced platform offers rapid and accurate testing capabilities aimed at significantly improving clinical decision-making processes. With a strong commitment to research and development, Alamar is poised to address unmet medical needs within the healthcare sector, presenting an attractive opportunity for institutional investors looking to capitalize on the growth potential in the diagnostics market.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?